A5026236319- Statistical Methods in Clinical Trials
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Causal Inference Techniques
- Cutaneous lymphoproliferative disorders research
- T-cell and Retrovirus Studies
- Optimal Experimental Design Methods
- Ocular Diseases and Behçet’s Syndrome
- Retinal and Optic Conditions
- Statistical Methods and Inference
- Statistical Methods and Bayesian Inference
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Computational Drug Discovery Methods
- Nail Diseases and Treatments
- Systemic Lupus Erythematosus Research
- Fungal Infections and Studies
- Meta-analysis and systematic reviews
- Carcinogens and Genotoxicity Assessment
- Vasculitis and related conditions
- Pharmacogenetics and Drug Metabolism
Université Paris Cité
2020-2024
Inserm
2020-2024
Centre de Recherche Épidémiologie et Statistique
2021-2022
Assistance Publique – Hôpitaux de Paris
2021-2022
Hôpital Saint-Louis
2021-2022
Columbia University
2022
Sorbonne Paris Cité
2021
Délégation Paris 7
2020
Propensity score (PS) matching is a very popular causal estimator usually used to estimate the average treatment effect on treated (ATT) from observational data. However, opting for this may raise some efficiency issues when sample size limited. Therefore, we aimed evaluate performance of propensity in context. We started with motivating example based cohort 66 children sickle cell anemia who received either allogeneic bone-marrow transplant or chronic transfusion. found substantial...
Mogamulizumab, an anti-CCR4 monoclonal antibody, has been shown to increase progression-free survival in cutaneous T-cell lymphoma.We hypothesized that besides the targeted depletion of Sézary cells (SCs), mogamulizumab may reshape immune tumour microenvironment.Both malignant and benign compartments from 26 patients with B2 stage syndrome before initiation were prospectively analysed using KIR3DL2 TCRVβ markers, serological markers molecular assessments clonality.Prior mogamulizumab, subset...
Dose-finding clinical trials in oncology estimate the maximum tolerated dose (MTD), based on toxicity obtained from clinician's perspective. While collection of patient-reported outcomes (PROs) has been advocated to better inform treatment tolerability, there is a lack guidance and methods how use PROs for assignments recommendations. The PRO continual reassessment method (PRO-CRM) proposed formally incorporate into dose-finding trials. In this paper, we propose two extensions PRO-CRM, which...
Given that novel anticancer therapies have different toxicity profiles and mechanisms of action, it is important to reconsider the current approaches for dose selection. In an effort move away from considering maximum tolerated as optimal dose, Food Drug Administration Project Optimus points need incorporating long-term evaluation, given many these agents lead late-onset or cumulative toxicities there are no guidelines on how handle them. Numerous methods been proposed in dose-finding...
Dose-finding trials aim to determine a safe dose be tested in larger for efficacy. In oncology, designs generally assume conventional monotonic increasing dose-toxicity relationships, mostly with binary outcomes (e.g., dose-limiting toxicity or not), measured the first cycle of therapy fixed number cycles. However, new anti-cancer agents such as molecularly targeted therapies and immunotherapies, late-onset toxicities have become more frequent. Designs prolonged observation windows censored...
The growing interest in new classes of anti‐cancer agents, such as molecularly‐targeted therapies and immunotherapies with modes action different from those cytotoxic chemotherapies, has changed the dose‐finding paradigm. In this setting, observation late‐onset toxicity endpoints may be precluded by treatment trial discontinuation due to disease progression, defining a competing event toxicity. Trial designs where is modeled framework survival risks model appear particularly well‐suited. We...
Dose-finding clinical trials in oncology aim to estimate the maximum tolerated dose (MTD), based on safety traditionally obtained from clinician's perspective. While collection of patient-reported outcomes (PROs) has been advocated better inform treatment tolerability, there is a lack guidance and methods how use PROs for assignments recommendations. The PRO continual reassessment method (PRO-CRM) proposed formally incorporate MTD, requiring complete follow-up both clinician patient toxicity...